Clinical Trial Search

Primary: Description of Signs and Symptoms of OIWS in Patients Who Scored Positive for Withdrawal Syndrome (OIWS) According to Diagnostic and Statistical Manual of Mental…

Primary: Oculo-Cognitive Addition Test (OCAT) Completion Time — 57.22; 57.22; 59.56; 58.18 seconds

Primary: Knowledge Gain — 30.6; 30.5; 27.56; 40.7 units on a scale

Primary: Area Under the Time Concentration Curve (AUROC ) — 0.9700 Probability

Primary: Abuse Liability Proxy — 0.197; 0.483; 0.159; 7.678 units on a scale (points 0-100) — p=<.05

Primary: To Measure the Association of Take-home Naloxone With Overdose Reversals Performed by Patients With Opioid Use Disorder Enrolled in an Opioid Treatment Program — 73; 263…

Primary: Overdose Risk Behavior — -1.54; -0.51 Scores on a scale

Primary: Respiratory Depression Following Opioids — -38.1; -37.1 percentage of change from baseline

Primary: Unused Opioids — 5; 10 oxycodone 5mg tablets

Primary: Time-weighted Average of SpO2 Below a Threshold of 90% — 0.29; 0.11; 0.16; 0.10 % of SpO2 — p=0.120

Primary: Change in Oxygenation (P/F Ratio) From Baseline to Final Pre-recovery Arterial Blood Gas (ABG) — 81; 80 mm Hg

Primary: The Number of Participants That Completed the Training in 6 Months — 55; 56; 10; 9 Participants

Primary: Overdose Risk Behaviors — 1.31; 1.21; 1.45; 1.25 score on a scale

Primary: Area Under the Curve (AUC) in COWS Total Score on Days 1 to 5 Inclusive — 4.2; 3.4 Average COWS score * hours

Primary: Change in Objective Opioid Withdrawal Score (OOWS) From Baseline (Prevention of Opioid Withdrawal) — 3.6; 3.6 units on a scale — p=0.87

Primary: Mean of the Change in Morphine Dosage (in mg) Required to Achieve 25% Reduction in Thermal Evoked Pain Responses Relative to Baseline (Pre-intervention) Placebo…

Primary: Rate of Fatal Opioid Overdose — 2; 6 Participants

Primary: Number of Participants Classified as Treatment Responders Within 12 Weeks — 59; 41 Participants

Primary: Pain Threshold — 18.72; 24.78; 16.16; 24.37 seconds

Primary: Summary of Visual Analog Scales (VAS) of Pain Intensity Change From Baseline by Treatment Group With Single Dose of Oxymorphone IR Tablet and Multiple Dose of…

Primary: Brain Regions With Increases or Decreases in Amplitude of Low Frequency Fluctuations (ALFF) Associated With Ondansetron Administration — 0.519; 0.562; 0.478; 0.486…

Primary: Change From Baseline in the Weekly Average of Spontaneous Bowel Movements (SBMs) During Treatment — 1.96; 3.42; 1.44 Number of SBMs/week

Primary: Number of Participants Retained in Study — 18 participants

Primary: Incidence and Severity of Treatment Emergent Adverse Events on Single Dosing. — 8; 5; 4; 6 participants

Primary: Odds of Morphine Equivalent Daily Dose (MEDD) of Opioid Prescription >=50 mg — 0.209; 0.417; 0.185; 0.364 odds of prescription high dose — p=0.956

Primary: Change From Baseline in Mean Weekly Spontaneous Bowel Movement (SBM) Frequency in Subjects Without Dose Reduction Prior to Week 8 — 2.4; 2.6 Spontaneous Bowel…

Primary: Clinically Meaningful Respiratory Compromise Events — 45 Events

Primary: Mean Weekly Spontaneous Bowel Movements at Week 8 — 2.4; 3.2 SBMs/Week

Primary: Mean Weekly Spontaneous Bowel Movements (SBMs) Per Month — 1.4; 4.9; 4.9; 5.0 Weekly SBMs

Primary: Pain Intensity Score of Oxymorphone IR Oral Liquid in Pediatric Subjects by Age Group and Time Points in Single Dose Phase — 4.5; 3.4; 2.4; 3.5 score on a scale